Neurological drugs developer Karuna Therapeutics is building up its pipeline with a pair of molecules initially developed for kidney disorders. It’s a small bet that could pay off in a big way by ...

Bristol Myers Squibb spent $14 billion in December on neurology biotech Karuna and its schizophrenia drug-in-waiting KarXT; now the focus is on launch plans and creating a franchise in a drug that ...

Drugmaker Bristol Myers BMY0.67%increase; green up pointing triangle Squibb reached a deal to buy neuroscience-drug developer Karuna Therapeutics for $14 billion. Under the terms, Bristol would pay ...

The fate of Karuna’s schizophrenia drug, KarXT, now rests with U.S. regulators after the company formally submitted its new drug application Thursday. The company had been projecting a third-quarter ...

The deal is a bet on the growing market for psychiatric and neurological drugs. By Lauren Hirsch Bristol Myers Squibb, the global pharmaceutical giant, said on Friday that it would acquire Karuna ...

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer’s drugmaker Karuna Therapeutics for $14 billion. Bristol Myers said it would pay $330 a share cash for ...

Bristol Myers Squibb (NYSE:BMY) out-maneuvered another large multinational pharmaceutical company in its $14B deal to acquire neurology-focused Karuna Therapeutics (KRTX) last month in a hard-won ...